Unfavorable Outcomes Associated With Glucocorticoid Use in Current Standard‐of‐Care Management of Systemic Lupus Erythematosus in Canada
- Published on 07/05/2024
- Reading time: 6 min.
Zahi Touma 1, Sheena Kayaniyil 2, Anna Parackal 2, Denisse Bonilla 1, Jiandong Su 1, Christina Qian 3, Sally D. Miller 3, Adam Johnston 4, James Gahn 4, Erik D. Hille 4, Robert Ohsfeldt 5, Shelly Chandran 2
1
Toronto Western Hospital
Toronto
Ontario
Canada
2
AstraZeneca
Mississauga
Ontario
Canada
3
Broadstreet Health Economics & Outcomes Research
Vancouver
British Columbia
Canada
4
Medical Decision Modeling Inc.
Indianapolis
Indiana
5
Medical Decision Modeling Inc., Indianapolis, Indiana, and Texas A&M School of Public Health
College Station
Abstract
Objective Our objective was to describe the administration of glucocorticoids (GCs) and characterize its association with organ damage in a longitudinal systemic lupus erythematosus (SLE) cohort over a time period spanning the introduction of biologics in Canada.
Methods A retrospective observational study was conducted using data from a large SLE cohort in Canada, including adults without lupus nephritis or central nervous system lupus. Patients were...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Rheumatology
Receive our newsletter to stay up to date with the latest news in Rheumatology
